138 related articles for article (PubMed ID: 2429947)
21. Collateral sensitivity to thaliblastine and/or hyperthermia exhibited by a rat ovarian tumor cell line selected for resistance to cisplatin.
Chen G; Zeller WJ; Todorov DK
Anticancer Res; 1993; 13(5A):1269-75. PubMed ID: 8239496
[TBL] [Abstract][Full Text] [Related]
22. Ormaplatin sensitivity/resistance in human ovarian cancer cells made resistant to cisplatin.
Parker RJ; Vionnet JA; Bostick-Bruton F; Reed E
Cancer Res; 1993 Jan; 53(2):242-7. PubMed ID: 8417816
[TBL] [Abstract][Full Text] [Related]
23. Augmentation of adriamycin, melphalan, and cisplatin cytotoxicity in drug-resistant and -sensitive human ovarian carcinoma cell lines by buthionine sulfoximine mediated glutathione depletion.
Hamilton TC; Winker MA; Louie KG; Batist G; Behrens BC; Tsuruo T; Grotzinger KR; McKoy WM; Young RC; Ozols RF
Biochem Pharmacol; 1985 Jul; 34(14):2583-6. PubMed ID: 4040369
[No Abstract] [Full Text] [Related]
24. Novel mechanisms of platinum drug resistance identified in cells selected for resistance to JM118 the active metabolite of satraplatin.
Samimi G; Kishimoto S; Manorek G; Breaux JK; Howell SB
Cancer Chemother Pharmacol; 2007 Feb; 59(3):301-12. PubMed ID: 16770583
[TBL] [Abstract][Full Text] [Related]
25. [Establishment of adriamycin-resistant human small-cell lung cancer cells in culture: analysis of the mechanism of resistance and cross-resistance].
Kimura I; Ohnoshi T; Hiraki S; Miyamoto H
Gan To Kagaku Ryoho; 1987 Mar; 14(3 Pt 2):830-6. PubMed ID: 3032107
[TBL] [Abstract][Full Text] [Related]
26. Effect of lung resistance-related protein on the resistance to cisplatin in human ovarian cancer cell lines.
Wang W; Ke S; Chen G; Gao Q; Wu S; Wang S; Zhou J; Yang X; Lu Y; Ma D
Oncol Rep; 2004 Dec; 12(6):1365-70. PubMed ID: 15547764
[TBL] [Abstract][Full Text] [Related]
27. In vitro selection and characterization of a bleomycin-resistant subline of B16 melanoma.
Zuckerman JE; Raffin TA; Brown JM; Newman RA; Etiz BB; Sikic BI
Cancer Res; 1986 Apr; 46(4 Pt 1):1748-53. PubMed ID: 2418953
[TBL] [Abstract][Full Text] [Related]
28. Adenoviral delivery of A-FOS, an AP-1 dominant negative, selectively inhibits drug resistance in two human cancer cell lines.
Bonovich M; Olive M; Reed E; O'Connell B; Vinson C
Cancer Gene Ther; 2002 Jan; 9(1):62-70. PubMed ID: 11916245
[TBL] [Abstract][Full Text] [Related]
29. Single step selection of cis-diamminedichloroplatinum(II) resistant mutants from a human ovarian carcinoma cell line.
McLaughlin K; Stephens I; McMahon N; Brown R
Cancer Res; 1991 Apr; 51(8):2242-5. PubMed ID: 1901242
[TBL] [Abstract][Full Text] [Related]
30. Changes in glutathione content and resistance to anticancer agents in human stomach cancer cells induced by treatments with melphalan in vitro.
Barranco SC; Townsend CM; Weintraub B; Beasley EG; MacLean KK; Shaeffer J; Liu NH; Schellenberg K
Cancer Res; 1990 Jun; 50(12):3614-8. PubMed ID: 2340510
[TBL] [Abstract][Full Text] [Related]
31. Comparative genomic hybridization analysis of chromosomal changes occurring during development of acquired resistance to cisplatin in human ovarian carcinoma cells.
Wasenius VM; Jekunen A; Monni O; Joensuu H; Aebi S; Howell SB; Knuutila S
Genes Chromosomes Cancer; 1997 Apr; 18(4):286-91. PubMed ID: 9087568
[TBL] [Abstract][Full Text] [Related]
32. [Establishment of adriamycin-resistant human ovarian carcinoma cell line and its mechanism of multidrug resistance].
Li PY; Lin C
Yao Xue Xue Bao; 1995; 30(4):258-62. PubMed ID: 7660793
[TBL] [Abstract][Full Text] [Related]
33. Regulation of HtrA2/Omi by X-linked inhibitor of apoptosis protein in chemoresistance in human ovarian cancer cells.
Yang X; Xing H; Gao Q; Chen G; Lu Y; Wang S; Ma D
Gynecol Oncol; 2005 May; 97(2):413-21. PubMed ID: 15863139
[TBL] [Abstract][Full Text] [Related]
34. Characteristics of bleomycin-resistant phenotypes of human cell sublines and circumvention of bleomycin resistance by liblomycin.
Lazo JS; Braun ID; Labaree DC; Schisselbauer JC; Meandzija B; Newman RA; Kennedy KA
Cancer Res; 1989 Jan; 49(1):185-90. PubMed ID: 2461797
[TBL] [Abstract][Full Text] [Related]
35. Modulation of cisplatin resistance in acquired-resistant nonsmall cell lung cancer cells.
Lai SL; Hwang J; Perng RP; Whang-Peng J
Oncol Res; 1995; 7(1):31-8. PubMed ID: 7549042
[TBL] [Abstract][Full Text] [Related]
36. Multidrug (pleiotropic) resistance in doxorubicin-selected variants of the human sarcoma cell line MES-SA.
Harker WG; Sikic BI
Cancer Res; 1985 Sep; 45(9):4091-6. PubMed ID: 4028002
[TBL] [Abstract][Full Text] [Related]
37. Increased platinum-DNA damage tolerance is associated with cisplatin resistance and cross-resistance to various chemotherapeutic agents in unrelated human ovarian cancer cell lines.
Johnson SW; Laub PB; Beesley JS; Ozols RF; Hamilton TC
Cancer Res; 1997 Mar; 57(5):850-6. PubMed ID: 9041185
[TBL] [Abstract][Full Text] [Related]
38. In vitro growth inhibition of cisplatin-resistant human lung cancer cell lines by recombinant human tumor necrosis factor and/or recombinant human interferon-gamma by virtue of collateral sensitivity.
Hong WS; Saijo N; Sasaki Y; Shinkai T; Eguchi K; Sakurai M; Takahashi H; Nakano H; Nakagawa K; Twentyman PR
Jpn J Cancer Res; 1987 Nov; 78(11):1274-80. PubMed ID: 3121562
[TBL] [Abstract][Full Text] [Related]
39. Collateral sensitivity to novel thymidylate synthase inhibitors correlates with folate cycle enzymes impairment in cisplatin-resistant human ovarian cancer cells.
Marverti G; Ligabue A; Paglietti G; Corona P; Piras S; Vitale G; Guerrieri D; Luciani R; Costi MP; Frassineti C; Moruzzi MS
Eur J Pharmacol; 2009 Aug; 615(1-3):17-26. PubMed ID: 19446547
[TBL] [Abstract][Full Text] [Related]
40. Apoptosis as a determinant of tumor sensitivity to topotecan in human ovarian tumors: preclinical in vitro/in vivo studies.
Caserini C; Pratesi G; Tortoreto M; Bedogné B; Carenini N; Supino R; Perego P; Righetti SC; Zunino F
Clin Cancer Res; 1997 Jun; 3(6):955-61. PubMed ID: 9815771
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
